Your Health, We Care
Palbociclib is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:
• an aromatase inhibitor as initial endocrine-based therapy; or
• fulvestrant in patients with disease progression following endocrine therapy.
FDA，2022.12
What is Palbociclib?Palbociclib is an oral anticancer drug whose active ingredie···【more】
Release date：2026-05-13Recommended：67
Indications and Combination Regimens of PalbociclibPalbociclib 125 mg capsules a···【more】
Release date：2026-05-12Recommended：63
Applicable for the treatment of adult patients with advanced or metastatic breas···【more】
Release date：2026-01-05Recommended：114
LuciusVersionofPalbociclib:DosageandAdministration,Indications,PrecautionsIndica···【more】
Release date：2025-12-05Recommended：151
Lucius Version of Palbociclib: Dosage and Administration, Indications, Precautio···【more】
Release date：2025-12-02Recommended：181
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
